Small Benefit, Persistent Toxic Risk With Adjuvant Anthracycline in Breast Cancer

(MedPage Today) -- Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk of heart failure, a randomized...